Tesamorelin vs CJC-1295: what to choose and for whom

The editorial team regularly receives the question «which is better - tesamorelin or CJC-1295?» The honest answer: this is not a question of preference, but of medical indications. Let's look at which groups of people each peptide was studied in, who might be a candidate for therapy, and for whom these substances are clearly unsuitable.

Why «what to choose» is above all a medical question

Both peptides stimulate the growth hormone-IGF-1 axis, and intervention in the endocrine system is never neutral. Even when the point is to enhance the body's own secretion rather than to administer a ready-made hormone, the changes affect carbohydrate metabolism, water balance, and the state of the joints and tissues.

That is why it is correct to frame the question this way: does the person have a condition in which stimulation of the GH axis is proven beneficial, and which drug is registered for it. This approach filters out most requests «for muscle definition» or «for recovery», which have no clinical justification.

Before prescribing, a doctor assesses the IGF-1 level, glycemia, any history of tumours, liver function and other parameters. Without such an examination it is impossible either to weigh benefit against risk or to notice complications at an early stage.

In addition, for athletes the choice is limited by the rules: both tesamorelin and CJC-1295 are on the WADA Prohibited List, so for people within the doping-control system both options are equally unacceptable.

Who tesamorelin was studied in

The main clinical-study population for tesamorelin is adults with HIV infection who are receiving antiretroviral therapy and have excess accumulation of visceral fat (lipodystrophy). It is precisely for them that the drug is FDA-approved under the brand name Egrifta.

In randomized trials, notably Falutz et al. (2007), tesamorelin reduced visceral fat compared with placebo. Stanley et al. (2014) showed a reduction in liver fat content, which became the basis for studies in non-alcoholic fatty liver disease in people with HIV.

The drug's label describes the dose used in clinical trials - 2 mg subcutaneously daily - as well as the need to monitor glucose and IGF-1. Common side effects include joint pain, injection-site reactions, edema and muscle pain.

The drug is contraindicated in pregnancy, in disorders of the hypothalamic-pituitary axis (for example, after pituitary surgery) and in active malignant processes. Efficacy in people without HIV-associated lipodystrophy has not been officially established.

Who CJC-1295 was studied in

The published studies of CJC-1295 with DAC were conducted mainly in healthy adult volunteers. Their aim was pharmacological: to determine how long the action lasts and how much GH and IGF-1 rise after one or several administrations.

The work by Teichman et al. (2006) showed a sustained rise in IGF-1, and Ionescu and Frohman (2006) showed preservation of pulsatile GH secretion against the background of stimulation. However, such studies do not answer the key question: does the drug bring clinical benefit in any disease.

The developer planned to study CJC-1295 including in HIV-associated lipodystrophy, but the development programme was discontinued. As a result, the drug did not obtain indications, a label or long-term safety data.

Consequently, CJC-1295 has no «target group» in the medical sense. Any use of it outside a research protocol is an experiment without product quality control and without knowledge of the consequences of prolonged use.

Who neither option is suitable for

There are groups for whom stimulation of the GH axis carries a particularly high risk. These include people with a history of cancer or with suspected tumours, since IGF-1 is a growth factor for many tissues.

People with diabetes or prediabetes need particular caution: growth hormone is a counter-regulatory hormone and can worsen glucose tolerance. In tesamorelin studies, a rise in glucose was one of the monitored adverse effects.

Pregnancy and breastfeeding, diabetic retinopathy, severe liver diseases are also situations in which a doctor will most likely decline such therapy.

Finally, no peptide is indicated for healthy young people without endocrine disorders who are seeking an aesthetic or athletic effect: there is no evidence of benefit for them, while the risks are real.

What actually works for the goals people seek these peptides for

Most often people are interested in reducing abdominal fat. For the general population, the best evidence base is held by a moderate calorie deficit, regular aerobic and strength training, and, in obesity, weight-control drugs approved by a doctor.

If the goal is natural support of growth hormone secretion, the most important factors are sufficient deep sleep, avoiding chronic sleep deprivation, a normal body weight and intense training. These factors influence GH pulsatility without pharmacological intervention.

If a genuine growth hormone deficiency is suspected, diagnosis is carried out according to clinical guidelines, notably those of the Endocrine Society, using stimulation tests. Treatment in such cases is usually recombinant growth hormone, not GHRH analogues.

In brief, the algorithm looks like this:

1. Formulate the goal and check whether it is a medical one.
2. Undergo examination: IGF-1, glucose, hormonal profile.
3. Discuss registered treatment options with an endocrinologist.
4. Decline unregulated «research» peptides.

Editorial conclusions

If we frame the question as «for whom», the answer is simple: tesamorelin has a clearly defined group of patients - adults with HIV-associated lipodystrophy, for whom a doctor prescribes it. CJC-1295 has no such group, because it did not complete clinical development.

For healthy people and athletes, neither peptide is a justified choice: there is no evidence of benefit, while the risks to carbohydrate metabolism and the anti-doping consequences are real.

Instead of choosing between two GH-axis stimulators, it is better to start with an examination and with the tools whose efficacy is proven: nutrition, training, sleep and medical supervision.

We also recommend reading our materials «Tesamorelin or CJC-1295: what's the difference», on the long-term risks of CJC-1295 and on how to tell a quality peptide from a counterfeit.

References

1. Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007;357(23):2359–2370.
2. Stanley TL, Feldpausch MN, Oh J, et al. Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial. JAMA. 2014;312(4):380–389.
3. Stanley TL, Fourman LT, Feldpausch MN, et al. Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial. Lancet HIV. 2019;6(12):e821–e830.
4. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab. 2006;91(3):799–805.
5. Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295, a long-acting GH-releasing hormone analog. J Clin Endocrinol Metab. 2006;91(12):4792–4797.
6. U.S. Food and Drug Administration. EGRIFTA (tesamorelin for injection): prescribing information. Silver Spring, MD: FDA.
7. Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2011;96(6):1587–1609.
8. World Anti-Doping Agency. The World Anti-Doping Code International Standard: Prohibited List. Montreal: WADA; актуальна редакція.